Hyloris Lays Out Ambitious Plans For US

Value Added Medicines Specialist Reveals How It Will Use IPO Proceeds

 
• By David Wallace
  
Stijin van_Rompay
Stijn Van Rompay lays out Hyloris’ strategy • Source: Hyloris
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Value Added Medicines

More from Products